View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Acta Derm Venereol. 2024 20;104:adv40737 doi: 10.2340/actadv.v104.40737
Renkhold et al. report that secukinumab significantly reduced psoriasis-associated pruritus intensity, improved skin lesions, and normalised histopathological changes, with stable neuroanatomy despite treatment discontinuation.
Arthritis Rheumatol. 2024 Sep 19 doi 10.1002/art.42993 Epub ahead of print
Deodhar et al. evaluated the efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis. The study found a significant improvement in the ASAS40 response at Week 16 (40.9% vs 22.9% in placebo, P<0.0001), with responses maintained through Week 52. No new safety signals were observed.
Arthritis Rheumatol 2024 doi: 10.1002/art.42997
IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.
Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062
Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.
Clin Exp Dermatol 2024;49:793–800 doi: 1093/ced/llad329
Following discontinuation of secukinumab 150mg or 300mg, a proportion of patients sustained low PASI with clear or almost clear skin despite being drug free for up to 2 years. Patients with a shorter disease duration were less likely to relapse, further supporting the hypothesis that earlier intervention with secukinumab may result in long-term control of moderate-to-severe psoriasis.
Br J Dermatol 2024;191:36–48 doi: 10.1093/bjd/ljad523
Thaçi, et al. show that guselkumab (GUS) had higher efficacy and a more tolerable safety profile compared with fumaric acid esters (FAE) in patients with moderate. Long-term efficacy through 100 weeks of treatment was seen with GUS as a first-line systemic treatment, and as a second-line systemic treatment in FAE nonresponders.
Br J Dermatol 2024;190:477–85 Doi: 10.1093/bjd/ljad429.
No new safety signals were found in the three-year safety data on bimekizumab for plaque PsO. Additionally, incidence of oral candidiasis significantly decreased with each subsequent year.
Ann Rheum Dis 2024 doi: 10.1136/ard-2024-225531 Epub ahead of print
The 2023 EULAR recommendations provided an updated consensus on the pharmacological management of PsA with a new overarching principle and recommendation for 2023. Recent MOA safety data emphasised the importance of patient-specific benefit-risk profiling in JAKi therapy, and extra-musculoskeletal (MSK) manifestations related to PsA should be considered during drug selection.
J Am Acad Dermatol 2017;76:418–31. doi: 10.1016/j.jaad.2016.11.042
Patients treated with guselkumab showed an improved and sustained clinical response compared to both adalimumab and placebo, without compromising safety profile. The Phase 3 VOYAGE 2 trial by Reich et al focused on treatment interruption and withdrawal, as well as treatment switching from adalimumab to guselkumab.
J Am Acad Dermatol 2017;76:405–17. doi: 10.1016/j.jaad.2016.11.041
Guselkumab demonstrated superiority to adalimumab and placebo in treating PsO in this Phase 3 study. Improvements in IGA and PASI scores were observed as early as Week 16 and were maintained up to Week 48. Incidence of adverse events was similar across both treatment groups.
